Free Trial

Minerva Neurosciences (NERV) Competitors

Minerva Neurosciences logo
$1.64 -0.01 (-0.61%)
As of 04:00 PM Eastern

NERV vs. KLRS, BLUE, ADVM, VRCA, DTIL, AADI, ATRA, RNXT, VTVT, and APLT

Should you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include Kalaris Therapeutics (KLRS), bluebird bio (BLUE), Adverum Biotechnologies (ADVM), Verrica Pharmaceuticals (VRCA), Precision BioSciences (DTIL), Aadi Bioscience (AADI), Atara Biotherapeutics (ATRA), RenovoRx (RNXT), vTv Therapeutics (VTVT), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry.

Minerva Neurosciences vs. Its Competitors

Kalaris Therapeutics (NASDAQ:KLRS) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

Kalaris Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.34, meaning that its share price is 134% less volatile than the S&P 500.

Minerva Neurosciences' return on equity of -20.68% beat Kalaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kalaris TherapeuticsN/A -62.08% -54.69%
Minerva Neurosciences N/A -20.68%15.73%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A
Minerva NeurosciencesN/AN/A$1.44M$0.822.00

Minerva Neurosciences has a consensus target price of $5.00, indicating a potential upside of 204.88%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Kalaris Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kalaris Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Minerva Neurosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 75.0% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 8.6% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Minerva Neurosciences had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 1 mentions for Minerva Neurosciences and 0 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 beat Minerva Neurosciences' score of -0.40 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Kalaris Therapeutics Neutral
Minerva Neurosciences Neutral

Summary

Minerva Neurosciences beats Kalaris Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NERV vs. The Competition

MetricMinerva NeurosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$11.54M$2.37B$5.44B$8.92B
Dividend YieldN/A1.78%5.22%4.00%
P/E Ratio2.008.8927.2520.05
Price / SalesN/A666.36426.50117.27
Price / Cash7.9021.7726.2128.59
Price / Book-0.454.507.925.57
Net Income$1.44M$31.26M$3.17B$248.56M
7 Day Performance-4.65%5.60%4.48%7.44%
1 Month Performance-10.33%5.93%2.80%8.43%
1 Year Performance-47.10%8.83%35.04%21.72%

Minerva Neurosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NERV
Minerva Neurosciences
3.9419 of 5 stars
$1.64
-0.6%
$5.00
+204.9%
-45.2%$11.54MN/A2.009News Coverage
Gap Up
KLRS
Kalaris Therapeutics
N/A$2.67
+1.9%
N/AN/A$49MN/A0.00110Positive News
Gap Up
BLUE
bluebird bio
2.1097 of 5 stars
$4.97
flat
$44.60
+797.4%
N/A$48.67M$103.95M-0.13520
ADVM
Adverum Biotechnologies
4.0895 of 5 stars
$2.15
-7.3%
$23.80
+1,007.0%
-65.4%$48.47M$1M-0.34190
VRCA
Verrica Pharmaceuticals
3.6153 of 5 stars
$0.53
+1.4%
$8.00
+1,409.1%
-91.0%$48.34M$7.57M-0.4440
DTIL
Precision BioSciences
4.5046 of 5 stars
$4.20
-2.3%
$47.00
+1,019.0%
-52.4%$47.68M$68.70M-2.09200
AADI
Aadi Bioscience
0.6437 of 5 stars
$1.93
+1.6%
$1.67
-13.6%
+49.6%$47.67M$25.07M-0.8540
ATRA
Atara Biotherapeutics
4.1086 of 5 stars
$7.72
-3.0%
$17.75
+129.9%
-3.3%$47.45M$128.94M-2.08330Gap Down
RNXT
RenovoRx
2.873 of 5 stars
$1.32
+2.7%
$7.25
+451.3%
+18.9%$46.81M$40K-3.296Positive News
VTVT
vTv Therapeutics
1.9217 of 5 stars
$15.00
+3.5%
$35.50
+136.7%
-23.0%$46.29M$1.02M-4.989
APLT
Applied Therapeutics
3.7932 of 5 stars
$0.31
-3.9%
$6.10
+1,860.8%
-92.5%$45.84M$460K-0.7230News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:NERV) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners